<DOC>
	<DOCNO>NCT02682238</DOCNO>
	<brief_summary>To assess safety local tolerability BBI-4000 15 % gel compare vehicle ( placebo ) apply topically daily subject palmar hyperhidrosis .</brief_summary>
	<brief_title>A Safety , Tolerability Preliminary Efficacy Study BBI-4000 Gel Subjects With Palmar Hyperhidrosis</brief_title>
	<detailed_description>This Multicenter , Randomized , Double Blind , Vehicle-Controlled Study Evaluate Safety Local Tolerability Topically Applied BBI-4000 ( Sofpironium Bromide ) 15 % Gel Subjects Palmar Hyperhidrosis . Participating subject apply either BBI-4000 15 % vehicle gel topically palms hand daily 4 consecutive week . The 4 week treatment period follow 2 week follow-up period . Safety tolerability assess collection vital sign , adverse event , assessment local skin response , ECG , UPT blood sampling . Efficacy assess gravimetric sweat assessment well Hyperhidrosis Disease Severity Scale ( HDSS ) .</detailed_description>
	<mesh_term>Hyperhidrosis</mesh_term>
	<criteria>Diagnosis primary palmar hyperhidrosis HDSS 3 4 baseline Gravimetric test baseline indicate least 100 mg sweat production rest palm sum least 250 mg palm , 5 minute ( room temperature ) Symptoms least 6 month ' duration Females childbearing potential must agree use medically acceptable method contraception participate study Any skin subcutaneous tissue condition palm , hyperhidrosis Prior use prohibit medication ( ) procedure ( ) within specify timeframe treatment palmar hyperhidrosis , include : 1 . Botulinum toxin palmar area within 9 month baseline visit 2 . Iontophoresis within 30 day baseline visit 3 . Palmar thermolysis , sympathectomy surgical procedure palmar area time past 4 . Serotonergic agonist within 30 day baseline visit 5 . Any topical prescription treatment hyperhidrosis within 30 day baseline visit 6 . Any overthecounter topical antiperspirant/deodorant within 7 day baseline visit Use anticholinergic agent within 30 day baseline visit Any oral topical homeopathic herbal treatment within 30 day baseline visit Use cholinergic drug within 30 day baseline visit Use antianxiety and/or antidepressant , amphetamine product drug know anticholinergic side effect Hyperhidrosis secondary know cause Subjects history unstable type 1 type 2 diabetes mellitus thyroid disease , history renal impairment , hepatic impairment , malignancy , glaucoma , intestinal obstructive motility disease , obstructive uropathy , myasthenia gravis , benign prostatic hyperplasia ( BPH ) , neurological condition , psychiatric condition , Sj√∂gren 's syndrome , Sicca syndrome , cardiac abnormality may alter normal sweat production may exacerbate use anticholinergic . Subjects know hypersensitivity glycopyrrolate , anticholinergic , component topical formulation . Pregnant lactating woman . Use investigational drug within 30 day prior baseline visit . Any major illness within 30 day screen examination .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>